
The FDA approved Sunharbo, the first factor XIa inhibitor, for certain adults after a recent ischemic stroke or high-risk TIA.
Approval covers adults after a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack.
The approved use is secondary prevention, and does not include people with atrial fibrillation or everyone with a prior stroke.
In the phase 3 OCEANIC-STROKE study, 12,327 adults received Sunharbo or placebo, with antiplatelet therapy in both groups.
Over a median 14.2 months, Sunharbo reduced ischemic stroke risk by 26% compared with placebo; this is a relative reduction.
Overall major bleeding rates were similar, but major bleeding increased among patients older than 75 and during the first 90 days.
FDA says certain enzyme-inducing medicines may reduce Sunharbo's effectiveness and does not recommend it for patients with moderate or severe liver impairment.
Explore the FDA announcement for the full approval details, trial findings, safety information, and medication restrictions described here.